...
首页> 外文期刊>Retina >Results of vitrectomy for breakthrough vitreous hemorrhage associated with age-related macular degeneration and polypoidal choroidal vasculopathy.
【24h】

Results of vitrectomy for breakthrough vitreous hemorrhage associated with age-related macular degeneration and polypoidal choroidal vasculopathy.

机译:玻璃体切割术治疗与年龄相关的黄斑变性和息肉样脉络膜血管病相关的突破性玻璃体出血的结果。

获取原文
获取原文并翻译 | 示例
           

摘要

PURPOSE: The purpose of this study was to evaluate the results of vitrectomy in patients with vitreous hemorrhage associated with age-related macular degeneration (AMD) and polypoidal choroidal vasculopathy (PCV). METHODS: A retrospective review was conducted of consecutive cases of patients undergoing pars plana vitrectomy for nonclearing vitreous hemorrhage associated with neovascular AMD or PCV. RESULTS: Twenty-four eyes of 23 patients were included. The mean length of time from the onset of vitreous hemorrhage to operation was 4.3 months. Twelve eyes had AMD, and 12 eyes of 11 patients had PCV. Additional treatments for active choroidal neovascularization or PCV were required in 12 eyes during follow-up. The mean visual acuity improved significantly from a logarithm of the minimum angle of resolution of 2.79 +/- 0.85 before operation to 1.61 +/- 0.98 at 2 months after operation (P < 0.001). Visual acuity was >or=20/200 in 9 eyes (37.5%) at 2 months after operation; 1 eye was in the AMD group, and the other eyes were in the PCV group. Improvement was more frequently observed in the PCV group (P = 0.005). CONCLUSION: In this series, the functional outcomes of vitrectomy for vitreous hemorrhage associated with AMD were inferior to outcomes of the PCV group. Vitrectomy is beneficial for improving visual function in select cases of breakthrough vitreous hemorrhage.
机译:目的:本研究的目的是评估玻璃体切除术治疗与年龄相关性黄斑变性(AMD)和息肉样脉络膜血管病(PCV)相关的玻璃体出血的结果。方法:回顾性研究了连续病例因未清除与新血管性AMD或PCV相关的玻璃体出血的玻璃体玻璃体切除术的患者。结果:纳入23例患者的24只眼。从玻璃体出血开始到手术的平均时间为4.3个月。 12眼患有AMD,11例患者的12眼患有PCV。随访期间需要对12只眼的活动性脉络膜新生血管或PCV进行其他治疗。平均视力从术前最小分辨角2.79 +/- 0.85的对数显着提高到术后2个月的1.61 +/- 0.98(P <0.001)。术后2个月9只眼(37.5%)的视力≥20/ 200;一只眼睛在AMD组中,另一只眼睛在PCV组中。 PCV组更常观察到改善(P = 0.005)。结论:在该系列研究中,玻璃体切除术治疗与AMD相关的玻璃体出血的功能结果不如PCV组的结果。玻璃体切除术在某些突破性玻璃体出血病例中有利于改善视觉功能。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号